Skip to content

GRCE

Grace Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$1.88
−0.53%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
-44.5%
EBIT
-44.5%
EPS
-30.1%
Free cash flow
+21.4%
Operating cash flow
+21.4%

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
+67.7%
EPS
+61.8%

Three-year CAGR

Revenue
—
EBITDA
+53.4%
EBIT
+53.4%
Net income
+42.8%
EPS
+58.4%
Free cash flow
+40.5%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026